Exchange: NASDAQ·Updated 04:33 PM EST

OCGN News

News
all
press releases
Ocugen's Q3 Earnings Match Estimates, Revenues Beat, Stock Rises
OCGN's Q3 revenues beat estimates. Shares surge 17.4%. Advancing gene therapy programs target three BLA submissions by 2028.
Zacks
Ocugen's Q3 Earnings Match Estimates, Revenues Beat, Stock Rises
OCGN's Q3 revenues beat estimates. Shares surge 17.4%. Advancing gene therapy programs target three BLA submissions by 2028.
Zacks
More News
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Ocugen (NASDAQ:OCGN) reported third-quarter financial results on Wednesday. The transcript from the company's third-quarter earnings call has been provided below.Benzinga APIs provide real-time access to earnings callread more...
Benzinga
Ocugen (OCGN) delivered earnings and revenue surprises of 0.00% and +34.55%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR NewswireNEW YORK, Oct. 8, 2026Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would...
PR Newswire
Ocugen (NASDAQ:OCGN) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial data.read more...
Benzinga
Ocugen is building an international pathway for OCU400 ahead of key Phase 3 data and a planned U.S. regulatory filing next year.
Stocktwits
Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028.
Zacks
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028.
Zacks

Advertisement|Remove ads.